NON-INSULIN DEPENDENT DIABETES MELLITUS (NIDDM) PRIMARY PREVENTION TRIAL

非胰岛素依赖型糖尿病 (NIDDM) 一级预防试验

• 批准号: 7627494
• 负责人: STEVEN M. HAFFNER
• 金额: $ 3.78万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7627494
• 关键词: Advertisements; Advertising; Albumins; Ankle; Blood Glucose; Communities; Computer Retrieval of Information on Scientific Projects Database; Development; Diabetes Mellitus; Diabetes prevention; Diabetic Neuropathies; End Point; Fasting; Funding; Glucose; Grant; Heart; Hyperglycemia; Institution; Insulin; Intervention; Life Style; Lipids; Lipoproteins; Metformin; Methods; Modification; Non-Insulin-Dependent Diabetes Mellitus; Persons; Pharmaceutical Preparations; Primary Prevention; Radio; Relative (related person); Research; Research Personnel; Resources; Retinal Diseases; Risk; Safety; Screening procedure; Secondary Prevention; Source; Staging; Standards of Weights and Measures; Television; Testing; Thick; United States National Institutes of Health; Universities; Upper arm; base; impaired glucose tolerance; prevent; urinary

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVE: As part of a multi-center grant (DK-93-07, non-insulin dependent diabetes mellitus primary prevention trial), we will attempt to prevent the development of NIDDM in 200 subjects with impaired glucose tolerance. RESEARCH PLAN: The Diabetes Prevention Trial (DPP) is a large multi-center study that tested the hypothesis that the use of intensive lifestyle modification or medications (metformin) could delay or prevent the onset of type 2 diabetes in persons who are at high risk for its development by virtue of having impaired glucose tolerance (IGT). Impaired glucose tolerance represents a less severe stage of blood glucose abnormalities and often precedes type 2 diabetes. METHODS: The primary research question for the DPP Trial is to determine the safety and efficacy of two interventions (intensive lifestyle or metformin) relative to a control intervention (standard lifestyle modifications) in delaying or preventing the onset of type 2 diabetes. Secondary endpoints include changes in lipids, lipoproteins, ankle/arm ratio, urinary albumin, and carotid wall thickness. Subjects will be obtained by several methods including: (a) community advertising through radio and television advertisements; (b) selective screening base from the University Center Downtown; and (c) subjects from the San Antonio Heart Study. Subjects identified with newly discovered diabetes but with normal fasting glycemia (2-hr glucose = 200 mg/dl, but fasting glucose 140 mg/dl) will be entered into a parallel secondary prevention trial to prevent the development of fasting hyperglycemia. In addition to the endpoints for the subjects in the primary prevention trial, these subjects will have assessment for diabetic neuropathy and retinopathy.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此，可以在其他清晰的条目中表示。列出的机构是 对于中心，这不一定是调查员的机构。 目的：作为多中心赠款的一部分（DK-93-07，非胰岛素依赖性糖尿病米洛蒂斯初级预防试验），我们将试图防止在200名患有葡萄糖耐受性受损的受试者中发展NIDDM。 研究计划：糖尿病预防试验（DPP）是一项大型的多中心研究，检验了以下假设：使用强化生活方式修饰或药物（二甲双胍）可能会延迟或阻止患有高风险的人的2型糖尿病发作由于葡萄糖耐受性受损（IGT）而发展。 葡萄糖耐受性受损代表了血糖异常的严重阶段，并且通常是2型糖尿病。 方法：DPP试验的主要研究问题是确定相对于对照干预措施（标准生活方式修改）的两种干预措施（强化生活方式或二甲双胍）的安全性和功效，以延迟或预防2型糖尿病的发作。 次要终点包括脂质的变化，脂蛋白，脚踝/臂比，尿白蛋白和颈动脉壁厚。 主题将通过几种方法获得：（a）通过广播和电视广告进行社区广告； （b）市中心大学中心的选择性筛查基地； （c）圣安东尼奥心脏研究的受试者。 用新发现的糖尿病确定的受试者，但会将正常的空腹血糖（2小时葡萄糖= 200 mg/dl，但禁食葡萄糖140 mg/dl）将被输入一项平行的二级预防试验，以防止快速饮食的发育。 除了初级预防试验中受试者的终点外，这些受试者还将对糖尿病神经病和视网膜病变进行评估。